Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity

Clinical Oncology

Volumn 27, Issue 10, 2015, Pages 579-587

  Barnett, G C ^a   Kerns, S L ^b   Noble, D J ^a   Dunning, A M ^c   West, C M L ^d   Burnet, N G ^c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

GWAS; Normal tissue; Radiosensitivity; Radiotherapy; SNP

Indexed keywords

BIOLOGICAL MARKER; GENETIC MARKER;

ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; PREDICTION; PRIORITY JOURNAL; RADIATION INJURY; RADIOGENOMICS; RADIOSENSITIVITY; ADVERSE EFFECTS; FEMALE; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; NEOPLASMS; PROCEDURES; RADIATION TOLERANCE;

FEMALE; GENETIC MARKERS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY;

EID: 84941315223     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.06.013     Document Type: Article

References (85)

1. Bentzen S.M., Heeren G., Cottier B., et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 2005, 75(3):355-365.
2. Ahmad A.S., Ormiston-Smith N., Sasieni P.D. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer 2015 Mar 3, 112(5):943-947.
3. IAEA Human Health Series No 14 Planning national radiotherapy services: a practical tool 2010, International Atomic Energy Agency, Vienna.
4. Cancer Research UK. Cancer statistics report: incidence UK, 2014. Available at: [accessed 04.03.15]. http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_INCIDENCE.pdf.
5. Cahlon O., Hunt M., Zelefsky M.J. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol 2008, 18(1):48-57.
6. Cozzarini C., Fiorino C., Di Muzio N., et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol 2007, 84(2):164-170.
7. Dearnaley D.P., Jovic G., Syndikus I., et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014, 15(4):464-473.
8. Donovan E., Bleakley N., Denholm E., et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity-modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007, 82(3):254-264. Breast Technology Group.
9. Mukesh M.B., Barnett G.C., Wilkinson J.S., et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 2013, 31(36):4488-4495.
10. Nutting C.M., Morden J.P., Harrington K.J., et al. PARSPORT trial management group. Parotid-sparing intensity-modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12(2):127-136.
11. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66(4):981-991.
12. Veldeman L., Madani I., Hulstaert F., De Meerleer G., Mareel M., De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9(4):367-375.
13. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1124-1129.
14. Cancer Research UK Research Strategy 2014. Available at: [accessed 03.06.15]. http://www.cancerresearchuk.org/sites/default/files/cruk_strategy.pdf.
15. Holthusen H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen und deren Nutzanwendung zur Verhütung von Schäden. Strahlentherapie 1936, 57:254-269.
16. Taylor A.M., Harnden D.G., Arlett C.F., et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 1975, 258:427-429.
17. Arlett C.F., Harcourt S.A. Survey of radiosensitivity in a variety of human cell strains. Cancer Res 1980, 40(3):926-932.
18. Loeffler J.S., Harris J.R., Dahlberg W.K., Little J.B. In vitro radiosensitivity of human diploid fibroblasts derived from women with unusually sensitive clinical responses to definitive radiation therapy for breast cancer. Radiat Res 1990, 121:227-231.
19. Plowman P.N., Bridges B.A., Arlett C.F., Hinney A., Kingston J.E. An instance of clinical radiation morbidity and cellular radiosensitivity, not associated with ataxia-telangiectasia. Br J Radiol 1990, 63:624-628.
20. Smith K.C., Hahn G.M., Hoppe R.T., Earle J.D. Radiosensitivity in vitro of human fibroblasts derived from patients with a severe skin reaction to radiation therapy. Int J Radiat Oncol Biol Phys 1980, 6:1573-1575.
21. Woods W.G., Byrne T.D., Kim T.H. Sensitivity of cultured cells to gamma radiation in a patient exhibiting marked in vivo radiation sensitivity. Cancer 1988, 62:2341-2345.
22. Puck T.T., Marcus P.I. Action of x-rays on mammalian cells. J Exp Med 1956, 103:653-666.
23. Deschavanne P.J., Debieu D., Fertil B., Malaise E.P. Re-evaluation of in vitro radiosensitivity of human fibroblasts of different genetic origins. Int J Radiat Biol 1986, 50(2):279-293. Erratum Int J Radiat Biol 1986;50(6):1129.
24. Little J.B., Nove J., Strong L.C., Nichols W.W. Survival of human diploid skin fibroblasts from normal individuals after X-irradiation. Int J Radiat Biol 1988, 54:899-910.
25. Malaise E.P., Fertil B., Deschavanne P.J., Chavaudra N., Brock W.A. Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts. Radiat Res 1987, 111:319-333.
26. Burnet N.G., Nyman J., Turesson I., Wurm R., Yarnold J.R., Peacock J.H. Improving radiotherapy cure rates by predicting normal tissue tolerance from in vitro cellular radiation sensitivity. Lancet 1992, 339:1570-1571.
27. Burnet N.G., Nyman J., Turesson I., Wurm R., Yarnold J.R., Peacock J.H. The relationship between cellular radiation sensitivity and tissue response to radiotherapy may provide the basis for individualising radiotherapy schedules. Radiother Oncol 1994, 33:228-238.
28. Geara F.B., Peters L.J., Ang K.K., Wike J.L., Brock W.A. Prospective comparison of in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int J Radiat Oncol Biol 1993, 27:1173-1179.
29. Johansen J., Bentzen S.M., Overgaard J., Overgaard M. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Oncol Biol Phys 1994, 66:407-412.
30. Peacock J., Ashton A., Bliss J., et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 2000, 55(2):173-178.
31. West C.M., Davidson S.E., Elyan S.A., et al. Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2001, 51(1):10-15.
32. Health Protection Agency Human radiosensitivity: report of the Independent Advisory Group on Ionising Radiation 2013, Available at:. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/333058/RCE-21_v2_for_website.pdf.
33. Zhao L., Wang L., Ji W., et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 2009, 74(5):1385-1390.
34. Anscher M.S., Murase T., Prescott D.M., et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 1994, 30(3):671-676.
35. Fu X.L., Huang H., Bentel G., et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001, 50(4):899-908.
36. De Jaeger K., Seppenwoolde Y., Kampinga H.H., Boersma L.J., Belderbos J.S., Lebesque J.V. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58(5):1378-1387.
37. Marks L.B., Bentzen S.M., Deasy J.O., et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S70-S76.
38. Carlomagno F., Burnet N.G., Turesson I., et al. Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities. Int J Cancer 2000, 85(6):845-849.
39. Badie C., Dziwura S., Raffy C., et al. Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. Br J Cancer 2008, 98:1845-1851.
40. Henriquez Hernandez L.A., Lara P.C., Pinar B., et al. Constitutive gene expression profile segregates toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Oncol 2009, 4:17.
41. Mayer C., Popanda O., Greve B., et al. A radiation-induced gene expression signature as a tool to predict acute radiotherapy-induced adverse side effects. Cancer Lett 2011, 302:20-28.
42. Ozsahin M., Crompton N.E., Gourgou S., et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005, 11(20):7426-7433.
43. Bourgier C., Lacombe J., Solassol J., et al. Late side-effects after curative intent radiotherapy: identification of hypersensitive patients for personalized strategy. Crit Rev Oncol Hematol 2015, 93(3):312-319.
44. Turesson I., Nyman J., Holmberg E., Odén A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 1996, 36:1065-1075.
45. Safwat A., Bentzen S.M., Turesson I., Hendry J.H. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 2002, 52(1):198-204.
46. Burnet N.G., Johansen J., Turesson I., Nyman J., Peacock J.H. Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int J Cancer 1998, 79:606-613.
47. Scott D. Chromosomal radiosensitivity and low penetrance predisposition to cancer. Cytogenet Genome Res 2004, 104:365-370.
48. Roberts S.A., Spreadborough A.R., Bulman B., Barber J.B., Evans D.G., Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?. Am J Hum Genet 1999, 65:784-794.
49. Curwen G.B., Winther J.F., Tawn E.J., et al. G(2) chromosomal radiosensitivity in Danish survivors of childhood and adolescent cancer and their offspring. Br J Cancer 2005, 93:1038-1045.
50. Curwen G.B., Cadwell K.K., Winther J.F., et al. The heritability of G2 chromosomal radiosensitivity and its association with cancer in Danish cancer survivors and their offspring. Int J Radiat Biol 2010, 86:986-995.
51. Finnon P., Robertson N., Dziwura S., et al. Evidence for significant heritability of apoptotic and cell cycle responses to ionising radiation. Hum Genet 2008, 123:485-493.
52. Schmitz A., Bayer J., Dechamps N., Goldin L., Thomas G. Heritability of susceptibility to ionizing radiation-induced apoptosis of human lymphocyte subpopulations. Int J Radiat Oncol Biol Phys 2007, 68:1169-1177.
53. Wu X., Spitz M.R., Amos C.I., et al. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 2006, 66:5993-5996.
54. Girard P.M., Kysela B., Harer C.J., Doherty A.J., Jeggo P.A. Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms. Hum Mol Genet 2004, 13:2369-2376.
55. Little J.B., Nove J. Sensitivity of human diploid fibroblast cell strains from various genetic disorders to acute and protracted radiation exposure. Radiat Res 1990, 123:87-92.
56. Barnett G.C., West C.M.L., Dunning A.M., et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009, 9(2):134-142.
57. Kerns S.L., West C.M., Andreassen C.N., et al. Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncol 2014, 10(15):2391-2406.
58. Alsner J., Andreassen C.N., Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008, 18:126-135.
59. Popanda O., Marquardt J.U., Chang-Claude J., Schmezer P. Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009, 667:58-69.
60. Talbot C.J., Tanteles G.A., Barnett G.C., et al. A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy. Br J Cancer 2012, 107(4):748-753.
61. Barnett G.C., Coles C.E., Elliott R.M., et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012, 13(1):65-77.
62. Barnett G.C., Elliott R.M., Alsner J., et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 2012, 105(3):289-295.
63. Kerns S.L., Ostrer H., Stock R., et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(5):1292-1300.
64. Kerns S.L., Stock R.G., Stone N.N., et al. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother Oncol 2013, 107(3):372-376.
65. Barnett G.C., West C.M.L., Coles C.E., et al. Standardized Total Average Toxicity (STAT) score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. Int J Radiat Oncol Biol Phys 2012, 82(3):1065-1074.
66. Barnett G.C., Thompson D., Fachal L., et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol 2014, 111(2):178-185.
67. Fachal L., Gómez-Caamaño A., Barnett G.C., et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet 2014, 46(8):891-894.
68. Andreassen C.N., Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009, 92:299-309.
69. West C., Rosenstein B.S., Alsner J., et al. Establishment of a radiogenomics consortium. Int J Radiat Oncol Biol Phys 2010, 76:1295-1296.
70. Burnet N.G., Elliott R.M., Dunning A., West C.M. Radiosensitivity, radiogenomics and RAPPER. Clin Oncol (R Coll Radiol) 2006, 18:525-528.
71. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006, 65:646-655.
72. Suga T., Ishikawa A., Kohda M., et al. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:685-693.
73. Fachal L., Gómez-Caamaño A., Peleteiro P., et al. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients. Radiother Oncol 2012, 105(3):321-328.
74. Kerns S.L., Ruysscher D.D., Andreassen C.N., et al. STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol 2014, 110(1):182-188.
75. Mavaddat N., Pharoah P.D., Michailidou K., et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 2015, 107(5). djv036.
76. West C.M., Barnett G.C. Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med 2011, 3(8):52.
77. West C.M., Dunning A.M., Rosenstein B.S. Genome-wide association studies and prediction of normal tissue toxicity. Semin Radiat Oncol 2012, 22:91-99.
78. Burnet N.G., Wurm R., Nyman J., Peacock J.H. Normal tissue radiosensitivity - how important is it?. Clin Oncol 1996, 8:25-34.
79. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25(4):231-241.
80. Khoo V.S., Dearnaley D.P. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer - the CHHiP trial. Clin Oncol (R Coll Radiol) 2008, 20(1):12-14.
81. Valdagni R., Rancati T., Ghilotti M., et al. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2009, 74(5):1431-1440.
82. Dehing-Oberije C., De Ruysscher D., Petit S., et al. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol 2010, 97:455-461.
83. Jaffray D.A., Lindsay P.E., Brock K.K., Deasy J.O., Tomé W.A. Accurate accumulation of dose for improved understanding of radiation effects in normal tissue. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S135-S139.
84. Scaife J.E., Harrison K., Romanchikova M., et al. Random variation in rectal position during radiotherapy for prostate cancer is up to three times higher than that predicted from prostate motion. Br J Radiol 2014, 87(1042):20140343.
85. Scaife J., Harrison K., Romanchikova M., Thomas S., Jena R., Burnet N.G. Accumulated dose volumes to the rectum are different from those planned in approximately 80% of patients treated with helical tomotherapy for prostate cancer. Clin Oncol 2015, 27(3):e3-e4.